Whale Team

[$Pistol Pete$]

$PMCB Stock Watch for PharmaCyte Biotech, Inc. (OTCPK:PMCB)


Market watchers might be keeping an eye on PharmaCyte Biotech, Inc. (OTCPK:PMCB)’s Piotroski F-Score. The F-Score was created to help spot company stocks that have solid fundamentals, and to filter out weaker companies. Piotroski’s F-Score uses nine tests based on company financial statements. PharmaCyte Biotech, Inc. (OTCPK:PMCB) currently has a Piotroski F-Score of 3. One point is provided for each piece of criteria that is met. Generally speaking, a stock with a high score of 8 or 9 would be viewed as strong, and a stock scoring on the lower end between 0 and 2 would be seen as weaker.

Currently, PharmaCyte Biotech, Inc. (OTCPK:PMCB)’s 6 month price index is 1.66307. The six month price index is calculated by dividing the current share price by the share price six months ago. A ratio above one indicates an increase in share price over the period. A ratio below one shows that there has been a price decrease over the time period. Investors tracking company shares may be also be analyzing the company’s FCF or Free Cash Flow. FCF is a measure of the financial performance of a company. FCF is calculated by subtracting capital expenditures from operating cash flow. Currently, PharmaCyte Biotech, Inc. (OTCPK:PMCB) has an FCF score of 0.951695. The FCF score is an indicator that is calculated by combining free cash flow stability with free cash flow growth. Typically, a higher FCF score value would indicate high free cash flow growth. The company currently has an FCF quality score of -7.025859. The free quality score helps estimate free cash flow stability. FCF quality is calculated as the 12 ltm cash flow per share over the average of the cash flow numbers. With this score, it is generally considered that the lower the ratio, the better.

Let’s also do a quick check on the Q.i. (Liquidity) Value. PharmaCyte Biotech, Inc. (OTCPK:PMCB) has a current Q.i. value of 67.00000. This value ranks stocks using EBITDA yield, FCF yield, earnings yield and liquidity ratios. The Q.i. value may help investors discover companies that are undervalued. A higher value would represent low turnover and a higher chance of shares being mispriced. A lower value may represent larger traded value meaning more sell-side analysts may track the company leading to a smaller chance shares are priced incorrectly.

When narrowing in on the Value Composite score for PharmaCyte Biotech, Inc. (OTCPK:PMCB), we notice that the stock has a rank of 75. This is using a scale from 0 to 100 where a lower score may indicate an undervalued company and a higher score would represent an expensive or possibly overvalued company. This rank was developed by James O’Shaughnessy in 2011. The score is derived from five different valuation ratios including price to book value, price to sales, EBITDA to Enterprise Vale, price to cash flow and price to earnings.